Seema Kumar is an Associate Director and senior DMPK project representative at EMD Serono Inc. (a business of Merck KGaA, Germany). In her role, Dr. Kumar provides overall NBE drug-disposition scientific support including Bioanalysis, Immunogenicity and DMPK/ADME strategy from concept generation through various development stages of the program. Previously, Dr. Kumar led regulated Bioanalytical group in BioMedicine Design (formerly PDM-NBE) department at Pfizer. The group provided regulated (GLP/GCP) support including PK, ADA and Nab assay development, validation and sample testing for pre-clinical and clinical programs. Prior to joining Pfizer, Dr. Kumar served at roles of increasing responsibility as Director of Quality Control and Director of CLIA certified Clinical Bioanalytical Lab at XBiotech USA Inc.
Dr. Kumar holds a Ph.D. from Johns Hopkins University and has published several publications in peer-reviewed journals and contributed to several book chapters. Dr. Kumar has given numerous talks in various national and international scientific conferences and meetings, and is an active member of industry consortia (IQ, AAPS